Author

M. P. Windisch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 5 Approach:experimental assay· 3 Organism:human· 3 Approach:statistical model· 3 Research Focus:benchmarking· 2 Research Focus:host-pathogen & immune response· 2 Approach:benchmark study· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

A. Ianevski· 5 shared A. Vitkauskiene· 4 shared E. Zusinaite· 4 shared M. Bjoras· 4 shared T. Tenson· 4 shared V. Oksenych· 4 shared D. E. Kainov· 3 shared R. Yao· 3 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

A. Ianevski

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Broad-spectrum mono- and combinational drug therapies for global viral pandemic preparedness

A. Ianevski, R. Yao, R. M. Simonsen, V. Myhre, E. Ravlo, G. D. Kaynova, E. Zusinaite, J. M. White, Q. Pan, S. J. Polyak, V. Oksenych, M. P. Windisch, E. Lastauskiene, A. Vitkauskiene, A. Matukevicius, , D. E. Kainov

The paper develops scoring systems to predict novel broad-spectrum antivirals and combinations, aiming to improve preparedness for future viral outbreaks.

bioRxiv · Jan 15, 2022 · PreprintMicrobiology

Interferon alpha-based combinations suppress SARS-CoV-2 infection in vitro and in vivo

A. Ianevski, R. Yao, E. Zusinaite, L. S. Lello, S. Wang, E. Jo, J. Yang, E. Ravlo, W. Wang, H. Lysvand, K. Loseth, V. Oksenych, T. Tenson, M. P. Windisch, M. Poranen, , D. E. Kainov

This study shows that IFNa-based combinations effectively inhibit SARS-CoV-2 infection in vitro and in vivo, with synergistic effects against other viruses.

bioRxiv · Jan 5, 2021 · PreprintMicrobiology

Identification of novel antiviral drug combinations in vitro and tracking their development

A. Ianevski, R. Yao, S. Biza, E. Zusinaite, A. Mannik, G. Kivi, A. Planken, K. Kurg, E.-M. Tombak, M. Ustav, N. Shtaida, E. Kulesskiy, E. Jo, J. Yang, H. Lysvand, , D. E. Kainov

This study identifies novel synergistic antiviral drug combinations effective against SARS-CoV-2, echovirus 1, HCV, and HIV-1 in vitro and provides an online resource for their developmental status.

bioRxiv · Sep 17, 2020 · PreprintMicrobiology

Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19

M. Ko, S. Y. Chang, S. Y. Byun, A. Ianevski, I. Choi, A. L. P. H. d'Alexandry d'Orengiani, D. Kainov, D. Shum, J.-Y. Min, M. P. Windisch

The paper screens FDA-approved drugs against a MERS-CoV isolate to identify potential therapies for COVID-19, finding several drugs with therapeutic indexes >6 and synergistic combinations.

bioRxiv · Feb 25, 2020Microbiology

Critical Nodes of Virus-Host Interaction Revealed Through an Integrated Network Analysis

K. Bosl, A. Ianevski, T. T. Than, P. I. Andersen, S. Kuivanen, M. Teppor, E. Zusinaite, U. Dumpis, A. Vitkauskiene, R. J. Cox, H. Kallio-Kokko, A. Bergqvist, T. Tenson, V. Oksenych, M. Bjoras, , R. K. Kandasamy

This study identifies critical host-virus interaction nodes through network analysis and drug re-purposing, revealing key targets for antiviral therapies.

bioRxiv · Feb 13, 2019 · PreprintImmunology